News

BD is conducting a voluntary medical device recall for multiple lots of the BD PosiFlush™ SF (Sterile Field) Saline Flush Syringe 10mL identified…

The Centers for Disease Control and Prevention (CDC) are currently soliciting written comments on pain and pain management, including those relevant to…

BD is conducting a voluntary medical device recall for multiple lots of the BD PosiFlush™ SF (Sterile Field) Saline Flush Syringe 10mL identified…

The National Hemophilia Foundation (NHF)  is seeking comments on draft ASH, ISTH, NHF and WHF clinical practice guidelines on VWD Diagnosis &…

The National Hemophilia Foundation’s (NHF’s) Medical and Scientific Advisory Council (MASAC) issued four new documents, which were adopted by NHF’s Board of…

Novo Nordisk recently announced that they have “paused” three clinical trials for their investigational subcutaneous therapy concizumab. The therapy is developed using…

As previously reported by HFA and NHF, Takeda announced the recall of two lots of VONVENDI von Willebrand factor (recombinant) 1,300 I.U….

Aptevo Theraoeutics has sold their recombinant factor IX product IXINITY® to Canada-based Medexus Pharmaceuticals. IXINITY®, which first received approval from the U.S….

The Partners in Bleeding Disorders Education Program has announced the launch a new version of “Understanding Hemophilia,” a six-part online learning activity for clinicians…

It is critical that an individual with a bleeding disorder who presents in an emergency department (ED) be triaged and administered care…

The National Hemophilia Foundation (NHF) has been monitoring the latest information on the current coronavirus (2019-nCoV) as it pertains to the bleeding…

Novo Nordisk has announced the launch of ESPEROCT®, the company’s long-acting recombinant factor VIII product for the prevention and treatment of bleeding…

An important new educational activity has launched for healthcare providers who practice in an emergency department setting. “Evaluation and Management of Hemophilia…

The U.S. Food and Drug Administration (FDA) has released several new gene therapy guidance documents to provide “regulatory clarity” for developers of…

Washington, D.C.—January 15, 2020— Patient and health advocacy groups representing millions of Americans with pre-existing conditions will file an amicus curiae or friend of the…

Please join us at NHF’s Bleeding Disorders Conference, August 6-8, 2020 in Atlanta, Georgia. Registration is now open! New this year! We…

Researchers from the Beth Israel Deaconess Medical Center in Boston, MA conducted a study on the link between postpartum hemorrhage (PPH) and…

Has your hematologist ever asked that your child have pharmacokinetic (PK) testing? Chances are, the doctor wants to know how factor behaves…

uniQure recently announced interim clinical trial data related to a phase IIb clinical study of etranacogene dezaparvovec (AMT-061), the company’s investigational gene…

The National Hemophilia Foundation (NHF) is pleased to announce that two educational activities in the “Clinical Advances in Gene Therapy for Hemophilia”…

A new observational study funded by Novo Nordisk, which is currently in the recruitment phase, will seek to better understand how hemophilia…

October 10, 2019 The National Hemophilia Foundation and the Hemophilia Federation of America continue to follow up on issues arising from Genentech’s recent…

October 9, 2019 Octapharma recently announced that their plasma-derived von Willebrand Factor (VWF)/Factor VIII (FVIII) product Wilate®, was approved by the U.S….

October 7, 2019 Today, Genentech provided the following statement regarding reports of particulate matter in vials of Hemlibra. You can read Genentech’s…